Dogwood Therapeutics Inc. is a biopharmaceutical company. It engages in developing a new class of non-opioid analgesics. The company focuses on the development of Halneuron, IMC-1 and IMC-2. Dogwood Therapeutics Inc., formerly known as Virios Therapeutics Inc., is based in Alpharetta, GA.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-34.26M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -108.57% |
| Return on Assets (Trailing 12 Months) | -30.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.33 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.15 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.90 |
| Diluted Earnings per Share (Trailing 12 Months) | $-10.60 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 33.63M |
| Free Float | 33.53M |
| Market Capitalization | $56.16M |
| Average Volume (Last 20 Days) | 0.08M |
| Beta (Past 60 Months) | 1.70 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |